Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eravacycline (Primary) ; Ertapenem
  • Indications Intra-abdominal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms IGNITE 1
  • Sponsors Tetraphase Pharmaceuticals

    • Most Recent Events

    • 14 Oct 2022 According to an Innoviva media release, XERAVA is approved by the European Commission (EC) for the treatment of complicated intra-abdominal infections in adults.
    • 15 Jan 2020 Results published in the Pharmacotherapy
    • 10 Jun 2019 According to a Tetraphase Pharmaceuticals media release, results of post-hoc analysis of two pooled phase 3 studies (IGNITE1 and IGNITE4) of XERAVA (Eravacycline) were presented at the 39th Annual Surgical Infection Society (SIS) Meeting (June 5th-8th, 2019).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top